According to zdfheute, Biontech envisions a future where the immune system is trained to recognize and target “highly personalized” cancer cells using mRNA technology. Sahin anticipates the approval of the first mRNA-based cancer vaccine by 2030. The potential breakthrough comes as Biontech commits to obtaining study data for various therapeutic approaches between 2025 and 2029.
Positive outcomes from these studies could pave the way for the approval of innovative cancer vaccines, ushering in a new era in medical science. Central to Biontech’s approach is cancer immunotherapy, a method that leverages the body’s natural defense system to combat cancer. Sahin emphasizes the significance of immunotherapies currently in clinical development for various cancers.
However, the goal is not just control but, ideally, the long-term cure of cancer. Biontech aims to create a technological framework capable of swiftly mapping out all the necessary steps for cancer treatment. This involves receiving a patient’s blood and tumor sample and delivering an individualized cancer vaccine within four weeks.
